Complete Response in Metastatic Breast Cancer with Trastuzumab and Doxorubicin
Author Information
Author(s): Kobrinsky Boris, Andreopoulou Eleni, Mourtzikos Karen, Muggia Franco
Primary Institution: New York University
Hypothesis
Can a combination of trastuzumab and pegylated liposomal doxorubicin lead to a complete response in patients with recurrent metastatic HER-2 positive breast cancer?
Conclusion
The patient achieved a complete response to the treatment combination of trastuzumab and pegylated liposomal doxorubicin.
Supporting Evidence
- The patient had a complete response documented by PET/CT after treatment.
- Trastuzumab has been shown to improve survival in women with HER2 overexpressing metastatic breast cancer.
- The combination of doxorubicin and trastuzumab has been associated with cardiac toxicity.
Takeaway
A woman with advanced breast cancer got better after taking two specific medicines together, which is a good sign for treating similar cases.
Methodology
Case report detailing treatment and response of a single patient with recurrent metastatic HER-2 positive breast cancer.
Limitations
This is a single case report, so results may not be generalizable to all patients.
Participant Demographics
59-year-old female business executive with recurrent metastatic HER-2 positive breast cancer.
Want to read the original?
Access the complete publication on the publisher's website